Clinical Trial Search

Primary: Change From Baseline in Serum Phosphorus Concentrations at the End of Treatment. — -1.84; -2.59; -3.17; -3.78 mg/dL

Primary: Adjusted Mean of Serum Phosphorus Concentrations at the End of Treatment — 5.00; 5.34 mg/dL — p=0.020

Primary: Incidence of Adverse Events — 28 Participants

Primary: Incidence of Adverse Events — 152 Participants

Primary: Change in Serum Phosphorus From Baseline to End of Treatment — -0.10; -1.86; -2.13 mg/dL — p=<0.0001

Primary: Change From Baseline in Serum-phosphate Levels at the End of Treatment. — -0.042; -0.348; -0.404; -0.644 mmol/L

Primary: Change in Serum Inorganic Phosphorus at the End of Treatment From Baseline — -0.26; -0.20 mg/dL

Primary: Serum Phosphate at Baseline — 7.47 mg/dL

Primary: Fractional Change in [PTH] in CKD After a 4-week Course of Sevelamer Carbonate — -11.7; 16.4 percentage of baseline [PTH]

Primary: Achieving Normal Serum Phosphorus Level — 36; 21 Participants — p=0.7439

Primary: Change From Baseline in Serum Phosphorus at Week 8 — 2.090; 2.095; 0.010; -0.200 mmol/L — p=<0.0001

Primary: Phosphorus Levels — 5.3; 5.6; 5.4; 6 mg/dL

Primary: Total Number of Episodes of Serum Potassium ≥ 5.5 mEq/L — 13; 41 episodes — p=0.024

Primary: Change in Serum Phosphate Concentration From Baseline (Visit 7, Day 1) to Visit 11 (Day 29) — -0.4; -0.59; -1.29; -1.363 mg/dL — p=0.784

Primary: Effect of Tenapanor to Achieve Target s-P Levels of Less Than or Equal to 5.5 mg/dL — 52; 58; 19 Participants

Primary: Serum Phosphorous Concentration — 2.0; 1.7 mg/dL

Primary: Change From Baseline in Serum Phosphorus at Day 22 (Genz-644470 vs Placebo) — -0.0; -0.6; -1.2; -1.8 mg/dL — p=0.0249

Primary: Change in Serum Phosphate Levels — -.47; -1.18; -1.7; -1.98 mg/dL — p=0.012

Primary: Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26) — 96; 58; 57; 93 participants — p=<0.0001

Primary: Serum Phosphorus Levels — 4.6; 4.6 mg/dL

Primary: Percent Change From Baseline in Parathyroid Hormone (PTH) During the Efficacy Period — -53.6; -55.6; -50.8 percent change

Primary: Placebo Adjusted Change in Serum Phosphate During Randomized Withdrawal Period From Pooled Tenapanor Arms — 1.4; 0.6 mg/dL — p=0.01

Primary: Fibroblast Growth Factor 23 (FGF-23) — 162.695; 297; 188.975; 143.7675 RU/ml

Primary: Change in Serum Phosphorus Levels During Placebo Controlled Randomized Withdrawal Period in the Responder Population — 0.43; 1.80 mg/dL — p=<0.0001

Primary: Serum Phosphorus — 3.9; 4.2 mg/dL

Primary: The Change in Serum Phosphorus for MCI-196 and Sevelamer — -1.23; -1.47; -2.26 mg / dL

Primary: The Percentage of Patients Reaching at Least a 30% Reduction in PTH and/or Values in Range 150-300 pg/mL — 96.6 Percentage of participants

Primary: Change From Baseline (Week 0) to Week 2 in Serum Phosphorus — 7.2; 7.2; 7.24; 6.34 mg/dL — p=0.001

Primary: Percent of Subjects That Achieved Controlled Serum Phosphorous Levels on Calcium-based Phosphate Binder Therapy — 14.9 percentage of subjects

Primary: Percentage of Subjects With ≥ 50% Decrease From Baseline in Intact Parathyroid Hormone (iPTH) Serum Level — 53.3; 41.9; 38.7; 56.7 Percentage of participants